RNS Hotlist with Zak Mir: I3E, DUKE, AVO, IQE, PLOB, MODE, ZPHR, POLX, HZM, SRES, BOD & ROQ via Vox Markets

It would appear that the fundamental momentum is continuing to grow at i3 Energy (I3E), an independent oil and gas company.


It said that due to the ongoing “exceptional” performance of its production assets, positive results from the initial phase of its 2022 development drilling programme, and continuing commodity price strength and the resultant positive impact on its cash flow projections, the company has decided to increase the minimum dividend to be paid in 2022 by 25% from £11.827mm to £14.784mm. The increase will be implemented by increasing the monthly dividend.

Duke Royalty (DUKE) said it has successfully raised £18.5 million at 35p. It has also raised £1.5 million via PrimaryBid. The Company’s Directors and their related parties have agreed to subscribe for 1,500,000 Placing Shares at the Issue Price.

Advanced Oncotherapy (AVO), the developer of LIGHT, noted the recent publication of two papers showcasing the potential superiority of the LIGHT system, over other existing proton therapy systems, in the delivery of FLASH.

IQE (IQE), the supplier of compound semiconductor wafer products, announced the world’s first commercially available 200 mm (8″) VCSEL epiwafer. The company said IQE’s 200mm epiwafers will enable a “step-change” in unit economics for compound semiconductors, leading to the expansion of the market for IQE.

Poolbeg Pharma (POLB), a clinical stage infectious disease pharmaceutical company, said it is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a Melioidosis vaccine candidate. Poolbeg currently holds an option from University College Dublin to licence a late pre-clinical stage Melioidosis vaccine (POLB 003).

Mode Global Holdings (MODE), the LSE-listed Fintech Group, announced a change to its board of directors with immediate effect. Current non-executive director, Gary Wilkinson and executive director Jonathan Conway have stepped down and Mike Robertson and David Shrier have been appointed to the board in their place as non-executive directors.

Zephyr Energy (ZPHR), the Rocky Mountain oil and gas company, provided an update on first quarter 2022 hydrocarbon sales from its non-operated asset portfolio in the Williston Basin, North Dakota, U.S. Q1 sales from the Company’s Williston Basin portfolio averaged circa 1,600 barrels of oil equivalent per day net to Zephyr, up from 548 boepd in Q4 2021. During the quarter, Zephyr sold 144,540 barrels of oil equivalent.

Polarean Imaging (POLX), the medical‑imaging technology company, announced that they have entered into a research collaboration to study the long-term effects of COVID-19 in patients who are still experiencing difficulty breathing months after the virus infection is gone, as part of the upcoming EXPLAIN study.

Horizonte Minerals (HZM), the nickel development company focused in Brazil, has awarded the earthworks contract for the construction of its 100%-owned Araguaia ferronickel project to Copa Construção S.A.

Sunrise Resources (SRES) said that it has applied to the California Department of Transport for conditional approval of CS natural pozzolan for use in California State infrastructure projects.

Caltrans is the Government body responsible for the award of State funded infrastructure construction projects in California.

Botswana Diamonds (BOD), the London AIM and BSE listed diamond explorer, said that, despite intensive advanced and ongoing discussions with interested parties, it has been unable to secure a new joint venture partner to acquire the Ghaghoo mine before the extended long-stop date of 10th May 2022. The Share Sale Agreement with Gem Diamonds Limited for the sale of its wholly owned subsidiary of Gem Diamonds Botswana Ltd, has therefore now lapsed.

Roquefort Therapeutics (ROQ), the Main Market listed biotech company, announced its audited results for period ended 31 December 2021. The company said it has made significant progress as a biotech entity which culminated in the acquisition of Lyramid and its pre-clinical drug development programmes in December 2021. It believes Lyramid to be a clear market leader in Midkine inhibiting RNA therapeutic drugs with its exclusive worldwide licence to commercialise up to 37 patents for the treatment of cancer patients, autoimmune disorders, chronic kidney disease and Covid-19.

Read More

Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.